Tspan14 expression and function in cardiovascular disease
Tspan14在心血管疾病中的表达和功能
基本信息
- 批准号:10656419
- 负责人:
- 金额:$ 9.94万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-07-01 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:Adaptor Signaling ProteinAddressAdvisory CommitteesAffectAllelesAnimal ModelApoptosisArchitectureBasement membraneBindingBinding SitesBioinformaticsBiologicalBiological ProcessBiologyBlood VesselsCD36 geneCardiovascular DiseasesCell membraneCell modelCellsCholesterolChromatinChromosomesCommittee MembersComplementComplexCoronary ArteriosclerosisCoronary heart diseaseDNADataDedicationsDevelopmentDiabetes MellitusDiseaseEndothelial CellsEndotheliumEnhancersExtracellular MatrixFosteringFutureGene ExpressionGene Expression RegulationGene TargetingGenesGeneticGenetic Enhancer ElementGenetic Predisposition to DiseaseGenetic VariationGrantGrowthHematological DiseaseHeritabilityHumanHyperlipidemiaHypertensionImmuneIntronsLaboratoriesLeadMacrophageMapsMeasuresMediatingMembraneMembrane MicrodomainsMentorsMesenchymalMinorModelingNucleic Acid Regulatory SequencesPathogenesisPathway interactionsPeptide HydrolasesPhasePopulation GeneticsProteinsReceptor ActivationRegulationRegulator GenesRegulatory ElementResearchResearch PersonnelRisk FactorsRoleScientistSignal TransductionSupervisionTechniquesTestingTissuesTrainingUntranslated RNAVariantVascular DiseasesVascular Endothelial CellWritingZebrafishactivation-induced cytidine deaminasecausal variantcell typedifferential expressiondisorder riskeffective therapyepigenetic regulationepigenomic profilingepigenomicsgenetic approachgenome editinggenome wide association studygenomic locusin vivoinsightmodel organismmonocytemortalitynew therapeutic targetnotch proteinnovelnovel strategiesprime editingprogramsprotective effectprotein functionprotein transportresponserisk variantskillssuccesstraffickingtranscription factortranscriptome sequencingtranscriptomicstransdifferentiation
项目摘要
PROJECT SUMMARY/ABSTRACT
Genetic predisposition is a significant risk factor for coronary artery disease (CAD), the leading cause of
mortality. Most CAD risk variants identified in genome-wide association studies (GWAS) are in noncoding
DNA, which poses a major challenge in identifying the target genes in the disease-critical cell types. Using the
Activity-by-Contact Model to predict cell type-specific gene-enhancer pairs, we identified cis-regulatory
elements in the chromosome 10q23 locus harboring multiple CAD-risk variants. Our preliminary studies show
that these enhancers in the 10q23 locus regulate tetraspanin 14 (TSPAN14) gene expression, specifically in
vascular endothelial cells (ECs) and monocytes. We have established strong population genetics evidence that
higher TSPAN14 expression reduces CAD risk and there is a consistent protective effect for the minor alleles
at the lead variants. TSPAN14 is an adaptor protein that aids in trafficking proteins like ADAM10, a Notch
receptor activator, to the plasma membrane. The role of Notch pathway activation imparted by this TSPAN14-
ADAM10 interaction in CAD pathogenesis has not been explored. In addition, we performed RNA-seq and
identified differentially expressed genes in TSPAN14-deficient cells that will help discover Notch-independent
TSPAN14 functions. These findings provide a premise for the central hypothesis that the genetic regulation of
TSPAN14 by variations in the 10q23 enhancer sequences affects CAD pathogenesis through Notch-
dependent and -independent mechanisms in vascular ECs and monocytes. In Aim 1, Dr. Lee-Kim will
determine the cell type-specific effect of 10q23 enhancer sequence variations on TSPAN14 expression
regulation. In Aim 2, she will determine the Notch-dependent effects of TSPAN14 expression in vascular and
immune cells. In Aim 3, she will characterize the Notch-independent TSPAN14 functions in vascular and
immune cells. The results from these studies will functionally validate the gene target for noncoding variants
associated with CAD-risk in the disease-relevant cell types and elucidate how TSPAN14 functions in CAD
pathogenesis. These studies will be conducted under the supervision of mentors, Dr. Rajat Gupta and Dr.
Stephen Blacklow, and an advisory committee dedicated to Dr. Lee-Kim’s success. With additional support
from the MOSAIC UE5 awardee sponsored professional development opportunities, continued training in the
K99 phase will prepare Dr. Lee-Kim for successful transition to independence.
项目总结/文摘
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Vivian Lee-Kim其他文献
Vivian Lee-Kim的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Vivian Lee-Kim', 18)}}的其他基金
Tspan14 expression and function in cardiovascular disease
Tspan14在心血管疾病中的表达和功能
- 批准号:
10851296 - 财政年份:2022
- 资助金额:
$ 9.94万 - 项目类别:
Tspan14 expression and function in cardiovascular disease
Tspan14在心血管疾病中的表达和功能
- 批准号:
10427604 - 财政年份:2022
- 资助金额:
$ 9.94万 - 项目类别:
Lysyl Oxidase Mutations in Cardiovascular Disease
心血管疾病中的赖氨酰氧化酶突变
- 批准号:
9533187 - 财政年份:2017
- 资助金额:
$ 9.94万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 9.94万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 9.94万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 9.94万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 9.94万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 9.94万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 9.94万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 9.94万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 9.94万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 9.94万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 9.94万 - 项目类别:
Research Grant














{{item.name}}会员




